489 results about "Type 2 diabetes" patented technology

Described herein are GLP-1R agonists and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of a GLP-1 associated disease or disorder, including Type 2 diabetes or obesity.

The invention discloses a coronary artery calcification early warning system for type 2 diabetes patients, and relates to the technical field of medical detection. A data acquisition module is used for acquiring continuous physiological parameter data of a user; the risk modeling module is combined with coronary artery calcification evolution characteristics in historical clinical samples to construct a multi-parameter dynamic association model; an index weight calculation unit generates a risk influence factor vector based on a sensitivity analysis result of the physiological indexes on risk prediction; the machine learning analysis module performs iterative training on the prediction model by adopting an integrated learning algorithm, and performs prediction updating by utilizing a risk influence factor vector; the early warning trigger module dynamically generates a graded early warning signal according to the grading trend and a set threshold value; the weak item positioning module carries out contribution degree analysis and anomaly recognition on the key risk indexes and automatically generates personalized intervention suggestions; according to the invention, early recognition and dynamic early warning of coronary artery calcification progress can be realized, and the method is suitable for intelligent early warning management scenes of chronic disease cardiovascular risks.

Described herein are GLP-1R agonists and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of a GLP-1 associated disease or disorder, including Type 2 diabetes or obesity.

The invention relates to the technical field of medical information processing, in particular to a type 2 diabetes precise typing and dynamic treatment system which comprises a clinical feature extraction module, a metabolism dynamic modeling module, a precise typing module, a treatment parameter generation module and a dynamic treatment output module. Wherein the clinical feature extraction module is used for collecting a multi-dimensional clinical data set of a patient for continuous 14 days; the metabolism dynamic modeling module is used for extracting blood glucose fluctuation characteristics and pancreas islet function compensation characteristics; the precise typing module is used for dividing metabolism-driven subtypes to which the patients belong through a clustering algorithm; the treatment parameter generation module is used for mapping a subtype-treatment rule base and outputting a matched personalized treatment parameter combination; and the dynamic treatment output module outputs a dynamic treatment scheme. According to the invention, through a dynamic treatment mechanism based on typing, linkage control of individual difference identification and real-time adjustment of the medication scheme of the type 2 diabetes patients is realized, and the accuracy and adaptability of treatment are improved.

The invention belongs to the technical field of medical instruments, and particularly relates to a cryoablation catheter and an ablation system.The cryoablation catheter comprises an inner catheter body and an outer catheter body, the outer catheter body is coaxially arranged on the outer side of the inner catheter body in a sleeving mode, and the inner catheter body is configured to be of a multi-cavity structure; the multiple plugging assemblies are arranged on the outer side of the inner catheter; wherein in the initial state, the multiple plugging assemblies and the inner catheter are located in the outer catheter, and in the working state, the multiple plugging assemblies and the inner wall of the intestinal tract jointly form an ablation closed space. The cryoablation catheter is guided to a target position through the guide wire, the closed ablation space is formed through cooperation of the plugging assembly and the inner wall of the cavity, a freezing medium is input into the closed ablation space to conduct cryoablation on the inner wall of the cavity, an available treatment scheme is provided for patients suffering from type 2 diabetes, obesity or other cavity lesions, and meanwhile the treatment effect is improved. The device has the advantages of small trauma, less pain of patients, low surgical risk and the like.

The present disclosure relates to a once weekly dosing regimen of a dual GLP-1R and GCGR agonist, formulations, and methods of using the same to induce weight loss in humans suffering from fatty liver disease, where the humans may or may not suffer from other complications, such as type 2 diabetes and / or cardiovascular disease / disorder. The dual agonist of the GLP-1R and the GCGR comprises a peptide product of SEQ ID NO. 1 (pemvidude), and a preparation method of the GLP-1R and GCGR dual agonist.

The present invention provides a compound having the basic structure shown by Formula (I) in which the indole ring and the pyrazolopyridine structure is bound through a substituent, a salt thereof or a solvate of either the compound or a salt of the compound, as well as a preventative agent or a therapeutic agent for non-insulin-dependent diabetes mellitus (Type 2 diabetes) or obesity containing such compound, salt or solvate as an active ingredient.

The invention provides a pancreatic islet organ capable of efficiently maintaining pancreatic islet beta cell identity and a preparation method and application thereof. Specifically, the invention provides the preparation method for the in-vitro pancreatic islet organ, and the preparation method comprises the following steps: carrying out induced differentiation culture on the ZnT8-knocked-out pluripotent stem cells, so as to obtain the mature pancreatic islet organ. The invention also provides a corresponding transplantation composition and application thereof. The invention discloses that ZnT8 knockout is a key factor for effectively maintaining the identity stability of beta cells in pancreatic islet organs. In addition, the pancreas islet beta cell identity maintenance agent is combined with the ZnT8-knocked-out pancreas islet organ for use, so that the identity stability of the pancreas islet organ beta cell can be obviously maintained. The invention provides a new strategy for transplantation treatment of type 2 diabetes, and has excellent clinical transformation value.

An artificially intelligent, voice-based method for prescribing, managing and administering at least one medication for management of type 2 diabetes to a patient. Aspects of the present disclosure provide for a system and method for configuring one or more clinical algorithms according to one or more clinical protocols to configure a conversational AI model. The conversational AI model is configured to drive a conversational AI agent configured to facilitate a plurality of multi-turn conversational interactions between a patient user and the conversational agent to enable automated initiation and titration of one or more diabetes medications for the patient.

The invention belongs to the technical field of biological medicines, and particularly relates to application of 1, 3-propane diamine or pharmaceutically acceptable salts thereof in preparation of medicines for preventing or treating diabetes. Experimental results show that 1, 3-propane diamine can obviously improve random blood glucose and fasting blood glucose of mice with type 2 diabetes mellitus, and 1, 3-propane diamine can obviously improve insulin resistance of model mice. According to the application, 1, 3-propane diamine is used for improving the blood sugar of patients with type 2 diabetes for the first time, an ideal treatment effect is achieved, a new treatment choice is provided for improving the blood sugar level through clinical application of 1, 3-propane diamine, and the application has extremely high application value and social benefits.

The invention discloses an application of a dendrobium extract in preparation of a medicine for treating type 2 diabetes, and mainly relates to the technical field of dendrobium. Particularly, the invention provides the dendrobium extract-containing medicine for treating the type 2 diabetes, so that the stability of components applied to the medicine for treating the type 2 diabetes in acidic, neutral and alkaline environments is improved, and the blood sugar rising amplitude is slowed down. Compared with the prior art, the medicine for treating type 2 diabetes mellitus prepared by the invention takes the dendrobium extract as a core and is matched with the synergistic emulsion, the rhizoma polygonati extract, the dogwood extract, the radix salviae miltiorrhizae extract, the bitter gourd extract, the vitamin B and the trace element chromium element; the traditional Chinese medicine composition disclosed by the invention can be used for synergistically regulating blood sugar metabolism, enhancing insulin sensitivity, improving microcirculation, stabilizing blood sugar, improving insulin resistance and lipid metabolism and enhancing immunity and cardiovascular functions, and a safe and effective medicine is provided for preventing and treating type II diabetes.

The invention belongs to the technical field of biological medicine, and particularly relates to application of hUC-MSCs combined with Met in preparation of anti-diabetic drugs. The diabetes mellitus is particularly type 2 diabetes mellitus. Through construction of a T2DM rat model, paraffin tissue section detection, serum ELISA, cell experiments and the like, researches prove that T2DM can be effectively treated by HUC-MSCs combined with Met treatment, including reduction of body blood sugar and recovery of blood sugar regulation ability; liver injury caused by T2DM is relieved and repaired; the glycolipid metabolism of the liver of the T2DM rat is improved; the immune inflammation disorder caused by T2DM is relieved; and the apoptosis level of liver cells is improved. And compared with a single hUC-MSCs or Met treatment mode, the combined treatment mode has a better treatment effect. The invention provides a theoretical basis and a new treatment strategy for treatment of T2DM.

The invention relates to the technical field of drug delivery systems. The invention provides an osmotic pump drug release system based on a fenerenone solid dispersion and a preparation method of the osmotic pump drug release system. According to the fenerenone solid dispersion prepared by adopting a hot melt extrusion technology and the osmotic pump drug release system based on the fenerenone solid dispersion, the solubility and the bioavailability of the fenerenone in the solid dispersion can be improved, and drug absorption can be accelerated; the sustained and stable release of the fenerenone can be realized, the drug release rate is optimized, the effectiveness and safety of the drug in the treatment process are ensured, the chemical stability of the fenerenone is improved, and the validity period of the drug is prolonged. Various challenges of the fenerenone in the using process are effectively solved, a more effective and safer treatment scheme is provided for patients suffering from chronic kidney diseases complicated with type 2 diabetes, and important practical value and wide market prospects are achieved.

The invention discloses a traditional Chinese medicine composition for treating type 2 diabetes and a preparation method and application thereof. The traditional Chinese medicine composition is prepared from, by weight, 11-15 parts of radix acanthopanacis semticosi, 5-15 parts of male silkworm moth, 7-17 parts of white ginseng, 5-11 parts of rhizoma polygoni cuspidati, 15-25 parts of rhizoma coptidis, 1-5 parts of cortex cinnamomi, 11-15 parts of fructus ligustri lucidi, 11-15 parts of common fenugreek seed, 7-17 parts of lithocarpus litseifolius, 3-7 parts of raw radix astragali and 1-3 parts of wild lucid ganoderma. , 3-9 parts of tribulus terrestris and 11-17 parts of nigella nigra seeds. The traditional Chinese medicine composition has the effect of balancing and stabilizing blood sugar, is short in treatment course, quick in effect and free of toxic and side effects, and has an excellent curative effect on treating diabetic complications.

A method for improving gut microbiota population in a subject by administering a composition comprising allulose, erythritol or a combination thereof. A method for increasing one or more colonic bacterial populations from the families Lachnospiraceae or Eubacteriaceae by administering a composition comprising allulose, erythritol or a combination thereof. A method for preventing, treating or ameliorating a disease in a subject by administering a composition comprising allulose, erythritol or a combination thereof. The disease may be one or more of metabolic syndrome, obesity, type 2 diabetes, insulin resistance, hyperlipoproteinemia, hyperuricemia, hepatic steatosis, hypercholesterolemia, hypertriglyceridemia, irritable bowel syndrome (IBS), colon cancer, allergy, non-alcoholic fatty liver disease, inflammatory bowel disease, cardiovascular disease, or inflammation. The bacterial population may be the species Anaerostipes hadrus, Blautia obeum, Anaerobutyricum hallii, Eubacterium rectale (Agathobacter rectalis), Eubacterium callanderi, Eubacterium limosum and Eubacterium maltosivorans. A composition comprising allulose, erythritol or a combination thereof and one or more colonic bacterial populations from the families Lachnospiraceae or Eubacteriaceae is also provided. The composition may in the form of a food composition.

The invention discloses a saussurea involucrata culture as well as a preparation method and application thereof, and belongs to the technical field of bioengineering and medicines. The invention relates to a saussurea involucrata culture, in particular to a selenium-rich and chromium-rich saussurea involucrata cell culture with DPP-IV inhibitory activity. The content of selenium in the saussurea involucrata culture reaches 200 mg / Kg dry weight or above, and the content of chromium Cr < 3 + > reaches 20 mg / Kg dry weight or above; in addition, chromium Cr < 6 + > is not detected, and the 70% ethanol extract of the saussurea involucrata cell culture is applied to an in-vitro DPP-IV inhibition test, and the inhibition rate of the 70% ethanol extract of the saussurea involucrata cell culture reaches 99.08%. The selenium-rich and chromium-rich saussurea involucrata culture with the high DPP-IV inhibition rate can be widely applied to preparation of medicines, health foods or functional foods for preventing and / or treating type 2 diabetes, obesity and related metabolic diseases.

The present invention discloses a traditional Chinese medicine composition for treating diabetes and a preparation method thereof, belonging to the technical field of traditional Chinese medicine compositions. The present invention solves the problem of limited curative effect existing in the treatment of existing diabetes. The present invention is composed of the following components: ginseng: 3-15 parts; poria cocos: 10-30 parts; atractylodes macrocephala: 5-30 parts; achyranthes bidentata: 10-30 parts; alisma orientale: 10-30 parts; rehmannia glutinosa: 10-30 parts; coptis chinensis: 5-30 parts; cinnamon: 3-20 parts; dried ginger: 5-20 parts; momordica grosvenori: 3-20 parts; corn stigma: 10-30 parts; lotus leaf: 3-20 parts; astragalus membranaceus: 10-30 parts; wolfberry: 10-20 parts; scrophularia ningpoensis: 5-15 parts; angelica sinensis: 5-15 parts; snow lotus flower: 5-10 parts; trogopterus dung: 5-10 parts; pyrrosia lingua: 5-10 parts. The present invention can be used for treating type 2 diabetes, has the functions of regulating blood sugar and enhancing body metabolism, and has remarkable curative effect.

The invention discloses a preparation method and application of a benzofuran component in eupatorium chinense. The benzofuran component is separated from an eupatorium chinense extract. The eupatorium chinense root extract is separated by using an extraction method, macroporous adsorption resin impurity removal, HW-40F gel column chromatography, high performance liquid chromatography and other methods to obtain the benzofuran compound. According to the present invention, the inhibition activity of the separated compound on the diabetes-related target alpha-glucosidase is tested, the experimental result shows that the compound has good inhibition activity on the alpha-glucosidase, and the molecular docking experiment shows that the compound has good binding energy with the target protein alpha-glucosidase. Therefore, the compound can be used for preparing drugs for preventing, delaying or treating alpha-glucosidase diseases, especially type II diabetes and obesity, or can be used as a lead compound of the drugs.

The invention discloses a biomarker of type 2 diabetes mellitus and application of the biomarker. The invention provides a group of new biomarkers and therapeutic targets, namely a combination of one or more of ACTN4, AHNAK, ATF4, ATP1A1, B2M, CYBA, GNB2, HES1, PRNP, TMBIM6, TSPAN13, VMP1 and YWHAE for the type 2 diabetes, by analyzing the expression level of the biomarkers, patients with the type 2 diabetes and non-diabetes can be effectively distinguished, a new scheme and way are provided for diagnosis and treatment of the type 2 diabetes, and the application of the biomarkers and the therapeutic targets is broad. The important clinical application value is realized.

Nutritional Cognitive Behavioral Therapy (Nutritional-CBT) is provided for the treatment of patients with type 2 diabetes and other cardiometabolic diseases, addressing common maladaptive thinking and beliefs pertaining to diet and lifestyle in a digitally-delivered therapy personalized to the individual patient using artificial intelligence (AI) / machine learning (ML) driven feed-back loops. Systems, methods, and computer-readable media described herein can include providing, by one or more processors, a digital therapeutic application including one or more lessons or activities. The one or more processors can collect at least one response or biometric data from the user. The one or more processors can generate, using a machine-learning model, one or more goals for the user to achieve or a progress overview.

The technical scheme of the invention discloses black fungus protein capable of reducing blood glucose and resisting oxidation as well as a preparation method and application of the black fungus protein. The amino acid sequence of the black fungus protein is as shown in SEQ ID NO. 1. The protein which is separated and identified from the black fungus for the first time and has the effects of reducing blood glucose and resisting oxidation achieves the effect of reducing blood glucose through double inhibition of alpha-amylase and alpha-glucosidase, meanwhile, the protein has remarkable antioxidant activity, animal experiments prove that fasting blood glucose and body weight of a type II diabetes model mouse can be effectively reduced, and the protein has a good application prospect. The compound has high biological activity and safety, and can be used for developing functional products with hypoglycemic and antioxidant activity.

Provided are a GLP-1GIP analog, an FGF21 protein, a trifunctional protein, and use thereof. The trifunctional protein comprises the GLP-1 / GIP analog and the FGF21 protein. Further provided is use of the GLP-1 / GIP analog, the FGF21 protein, and the trifunctional protein in the preparation of a drug for preventing and / or treating diseases related to GLP-1, GIP, and / or FGF21. The provided GLP-1 / GIP analog, FGF21 protein, and trifunctional protein can synergistically regulate blood glucose and lipid levels in vivo, meet multiple needs in patients with type 2 diabetes, including lowering blood glucose, alleviating hepatic steatosis, promoting weight loss, ameliorating circulating lipid metabolism disorder, etc., and have better biological safety and tolerability and longer in vivo half-lives.

The invention discloses a GLP-1 GIP analogue, an FGF21 protein, a three-function protein and an application thereof. The trifunctional protein comprises a GLP-1 / GIP analogue and an FGF21 (Fibroblast Growth Factor 21) protein. The invention also discloses application of the GLP-1 / GIP analogue, the FGF21 protein and the three-function protein in preparation of medicines for preventing and / or treating diseases related to GLP-1, GIP and / or FGF21. The GLP-1 / GIP analogue, the FGF21 protein and the three-function protein provided by the invention can synergistically regulate blood sugar and lipid levels in vivo, meet multiple requirements of patients with type 2 diabetes for reducing blood sugar, relieving liver fatty degeneration, reducing weight, improving circulating lipid metabolism disorder and the like, and are better in biological safety and tolerance and longer in in-vivo half-life period.

An artificially intelligent, voice-based method for prescribing, managing and administering at least one medication for management of type 2 diabetes to a patient. Aspects of the present disclosure provide for a system and method for configuring one or more clinical algorithms according to one or more clinical protocols to configure a conversational AI model. The conversational AI model is configured to drive a conversational AI agent configured to facilitate a plurality of multi-turn conversational interactions between a patient user and the conversational agent to enable automated initiation and titration of one or more diabetes medications for the patient.

Provided herein are quinazolinone compounds for modulating muscle myosin to treat obesity and related disorders such as cardiovascular diseases, type 2 diabetes, obstructive sleep apnea, cancer, and osteoarthritis.

Provided herein are methods of treating type 2 diabetes (T2D) using a novel dosing regimen of a GIP:GLP-1 Peptide having a GIP:GLP-1 receptor agonist potency ratio that is about 2.5:1 to about 10:1 GIP to GLP-1. Also provided herein are methods of treating T2D using a novel dosing regimen of a GIP:GLP-1 Peptide having a GIP:GLP-1 receptor agonist potency ratio that is about 2.5:1 to about 5:1 GIP to GLP-1.

The invention relates to a mitochondrial uncoupling inhibitor sustained-release nanodot, a preparation method thereof and application of the nanodot in type 2 diabetes mellitus, and belongs to the technical field of nano-drugs. According to the preparation method disclosed by the invention, glycine and genipin are subjected to Schiff reaction to prepare the slow-release nanodot, and the slow-release nanodot is of a monodisperse spherical structure, has surface negative charges, and can slowly release genipin under physiological conditions, so that the mitochondrial protection effect of the genipin is fully exerted. The mitochondrial uncoupling inhibitor slow-release nanodot prepared by the invention can obviously improve the mitochondrial membrane potential, increase the cell ATP content, effectively inhibit mtDNA release under the stimulation of IL-1beta and palmitic acid, effectively inhibit STING inflammation pathway activation under the stimulation of IL-1beta and PA, obviously reduce pancreatic beta cell apoptosis, obviously relieve endoplasmic reticulum stress, and can be used for preparing the mitochondrial uncoupling inhibitor slow-release nanodot. The T2DM mouse blood sugar is obviously reduced, the glucose tolerance dose and the insulin sensitivity are improved, and good biocompatibility is achieved.

Described herein is GLP-1R agonists and pharmaceutical compositions comprising the said compound. The subject compound and compositions are useful for the treatment of a GLP-1 associated disease or disorder, including Type 2 diabetes or obesity.

The present disclosure relates to methods of treating, preventing or managing cardiovascular and / or metabolic disorders selected from the group consisting of hypercholesteremia, dyslipidemia, hypertriglyceridemia, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), type 2 diabetes and obesity in a human subject in need thereof by administering a human FGF21 protein variant.

Compositions and formulations of synthetic MXRA8-Fc fusion proteins are provided, as well as methods of use thereof. Methods include neutralizing TSP1 / MXRA8 interactions in a subject by administering a synthetic MXRA8-Fc fusion protein, such that the synthetic MXRA8-Fc fusion protein binds to TSP1 to inhibit the TSP1 from binding with MXRA8. Methods also include treating obesity such as high fat diet (HFD)-induced obesity, and treating obesity-associated metabolic diseases such as type 2 diabetes by administering a synthetic MXRA8-Fc fusion protein.